Chronic myelogenous leukemia

JAMA

Volumn 286, Issue 8, 2001, Pages 895-898

  Kalidas, M ^a   Kantarjian, H ^a   Talpaz, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; CYTOSINE DERIVATIVE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TROXACITABINE; UNCLASSIFIED DRUG; VACCINE;

ANOREXIA; ARTHRALGIA; CHILL; CHRONIC MYELOID LEUKEMIA; FATIGUE; FEVER; FLUID RETENTION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPE; MALIGNANT TRANSFORMATION; NAUSEA; PATHOPHYSIOLOGY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL TRANSPLANTATION; VOMITING; WEIGHT REDUCTION;

EID: 0035934067     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.8.895     Document Type: Review

References (48)

1. Chronic myelocytic leukemia
2. A minute chromosomal abnormality in human chronic granulocytic leukemia
3. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining
4. Ph positive acute lymphoblastic leukemia in adults
5. The molecular genetics of Philadelphia chromosome-positive leukemias
6. Medical progress
7. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
8. Interferon-alpha sustained cytogenetic responses in chronic myelogenous leukemia
9. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha
10. Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase
11. RT-PCR studies in patients with chronic myeloid leukemia (CML) in remission 5 years after allogeneic stem cell transplant (SCT) define risk of subsequent relapse
12. Chronic myelogenous leukemia
13. Chronic granulocytic leukemia
14. Busulfan in the treatment of chronic myelocytic leukemia
15. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia
16. The evolution of hydroxyurea therapy in chronic myelogenous leukemia
17. Low dose interferon-alpha 2b combined with hydroxyurea versus hydroxy-urea alone for chronic myelogenous leukemia
18. Approaches to the treatment of chronic myelogenous leukemia
19. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia
20. UK Medical Research Council randomized, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia
21. Prolonged survival following achievement of cytogenetic response with alpha-interferon therapy in chronic myelogenous leukemia
22. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia
23. Hydroxyurea therapy in chronic myelogenous leukemia
24. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin
25. The treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation
26. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
27. Allogeneic bone marrow transplantation for CML
28. Bone marrow transplantation for chronic myeloid leukemia
29. Treatment of chronic myeloid leukemia by marrow transplantation
30. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia
31. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplant
32. Therapeutic choices in younger patients with chronic myelogenous leukemia
33. Cytarabine increases karyotypic response in alpha-IFN treated chronic myeloid leukemia patients
34. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia
35. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
36. Prognostic discrimination in "good risk" chronic granulocytic leukemia
37. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
38. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
39. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
40. A phase II study of STI-571 in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in accelerated phase
41. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
42. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
43. Phase II study of STI-571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
44. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
45. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
46. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
47. Troxacitabine, a novel nucleoside analog is active in acute and chronic myeloid leukemia
48. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia